New form of modified release dose with xantina oxidase inhibitor or xantina oxidase inhibitor

摘要

It refers to a pharmacological component, which includes: (a) the field of immediate release of febuxstat, with a content of 20% to 40% by weight of the component, including (I) an inert nucleon, with a content of 50% to 55% P / P, with a weight of immediate release range; (II) a direct release layer encapsulated in an inert core, consisting of a mixture of febuxstat and hydroxypropylmethylcellulose, with a content of 45-50% by weight of the direct release range, wherein the ratio of febuxstat to hydroxypropylmethylcellulose is 1.5-3; and (b) the field of delayed release of febuxstat Calculated by weight of 60% to 80%It includes: (1) the inert core with a delayed release range weight of 40.5-43% P / p; (2) the direct release layer encapsulated in the inert core, which contains a mixture of febuxstat and hydroxypropylmethylcellulose with a content of 35-40% of the delayed release range weight; (3) a complete polymer layer with delayed release, encapsulated in an immediate release layer of 17% to 20% P / P by weight of the delayed release range, including a mixture of type A and type B metabolic acid copolymers;(4) a plasticizer, such as triethyl citrate, having a delayed release range weight of 1-3% P / P. This kind of pharmacological synthesis is an effective method to treat gout